Changes in Adrenoceptor and GRK Expression in Patients With Chronic Pulmonary Regurgitation

Rodríguez‐Serrano, María; Soriano, Joaquín Rueda; Fuentes, Francisco Buendía; Sáez, Ana M. Osa; Guillot, F; Navaza, Pilar D’Ocon; Agüero, Jaume; Oliver, Eduardo; Serrano, Félix; Martínez‐Dolz, Luis

doi:10.1016/j.rec.2018.05.030

Cited by 1 publication

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the five genes studied, a markedly lower expression of GRK2, and β2-ARs in PBMC was found in the group of patients with PR vs. controls, as we described previously (Rodríguez-Serrano et al, 2018), together to a slight decrease in the GRK3 expression. However, the more interesting contribution of the present work is that the reduced expression of GRK2 and β2-ARs was found not only in symptomatic patients (NHYA ≥ 2 class) but also in asymptomatic patients (NHYA 1 class).…”

Section: Discussionsupporting

confidence: 84%

“…In a previous work (Rodríguez-Serrano et al, 2018), we have found that patients with severe PR had lower genic expression of β2-AR and GRK2 in PBMCs. In the present study, the group of patients with severe PR also exhibit a significantly lower expression of β2-AR (PR, 513.8 ± 261.2 copies of mRNA) vs. healthy volunteers (control, 812.5 ± 497.2 copies of mRNA).…”

Section: Resultsmentioning

confidence: 68%

“…In a previous work we have found that the gene expression pattern of GRK2 and the β2-AR was altered in patients with severe PR in a similar way to patients with advanced HF (Rodríguez-Serrano et al, 2018). In the present work, we propose a molecular approach to improve the pathophysiological knowledge of PR in order to help us to decide the right time for PVR.…”

Section: Introductionmentioning

confidence: 71%

“…We have shown that β2-AR and GRK2 expression decrease in PBMC from patients with severe PR vs. healthy volunteers, as occurs in HF patients (Rodríguez-Serrano et al, 2018). Therefore, the expression of both genes in PBMC could be an interesting marker of the evolution of the PR patients.…”

Section: Discussionmentioning

confidence: 89%

“…Patients included in this study are part of the cohort of PR patients recruited in a previous study (Rodríguez-Serrano et al, 2018) that has been submitted to pulmonary valve replacement (PVR) and clinically followed by one year. PVR was carried out on patients who met criteria according to the guidelines of clinical practice (Warnes et al, 2008; Baumgartner et al, 2010).…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

β2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation

et al. 2019

Self Cite

View full text Add to dashboard Cite

Pulmonary regurgitation (PR) is a frequent complication after repair of congenital heart disease. Three different GRK isoforms (GRK2, GRK5, and GRK3) and two β-adrenoceptors (β1-AR and β2-AR) are present in peripheral blood mononuclear cells (PBMC) and their expression changes as a consequence of the hemodynamic and neurohumoral alterations that occur in some cardiovascular diseases. Therefore, they could be useful as biomarkers in PR. A prospective study was conducted to describe the expression (TaqMan Gene Expression Assays) of β-ARs and GRKs in PBMC isolated (Ficoll ® gradient) from patients with severe PR before and after pulmonary valve replacement and establish if this expression correlates to clinical status. 23 patients with severe PR were included and compared with 22 healthy volunteers (controls). PR patients before the PVR had a significantly lower expression of β2-AR (513.8 ± 261.2 mRNA copies) vs. controls (812.5 ± 497.2 mRNA copies), so as GRK2 expression (503.4 ± 364.9 copies vs. 858.1 ± 380.3 mRNA copies). The expression of β2-AR and GRK2 significantly decreases in symptomatic and asymptomatic patients, as well as in patients under treatment with beta-blockers and non-treated patients. The expression of β2-AR and GRK2 in PR patients recovers the normal values after pulmonary valve replacement (754,8 ± 77,1 and 897,8 ± 87,4 copies, respectively). Therefore, changes in the expression of β2-AR and GRK2 in PBMC of PR patients, could be considered as potential biomarkers to determine clinical decisions.

show abstract